Articles by Aman Chauhan, MD
Dr. Soares addresses how understanding regulatory pathways benefits the multidisciplinary teams managing patients with NETs. A shared understanding of pathway terminology, particularly what a 505(b)(2) product represents, creates a common language among nuclear medicine physicians, medical oncologists, pharmacists, and radiation oncologists. This clarity reduces confusion about whether a therapy is truly novel, generic, or something in between, and directly improves the efficiency of tumor board discussions, formulary committee reviews, and patient counseling. Without this shared vocabulary, discussions stall on terminology rather than advancing to the clinically important questions of patient selection, access, and operational implementation.
Dr. Aman Chauhan introduces the program on radioligand equivalents and the 505(b)(2) pathway in neuroendocrine tumor (NET) treatment, joined by Dr. Andrew Hendifar, Dr. Heloisa Soares (medical director of the theranostics program at University of Utah), and Dr. Ghassan El-Haddad (vice chair for radiopharmaceutical and nuclear oncology at Moffitt Cancer Center, nuclear medicine physician and interventional radiologist).
Obrixtamig in combination with platinum-based chemotherapy demonstrated encouraging clinical activity in patients with DLL3-positive neuroendocrine carcinomas, with high response rates and durable disease control. The regimen showed a manageable safety profile, with adverse events consistent with its mechanism and no unexpected toxicities. These findings support further development of this combination as a potential first-line treatment option.
Theranostics and Management of NETS Going Forward
ByNamrata (Neena) Vijayvergia, MD,Junaid Arshad, MD, MS,Aman Chauhan, MD,Andrew E. Hendifar, MD,Shagufta Shaheen, MD Discover the future of cancer treatment with innovative therapies and groundbreaking research in radiopharmaceuticals and theranostics.
CAR-T and Radioligand Therapies for Treatment of NETS
ByNamrata (Neena) Vijayvergia, MD,Junaid Arshad, MD, MS,Aman Chauhan, MD,Andrew E. Hendifar, MD,Shagufta Shaheen, MD Experts discuss the promising future of CAR-T therapy and radioligand treatments for neuroendocrine tumors, highlighting new trials and potential breakthroughs.
Sequencing and Place of Cabozantinib in NETS Treatment Algorithm
ByNamrata (Neena) Vijayvergia, MD,Junaid Arshad, MD, MS,Aman Chauhan, MD,Andrew E. Hendifar, MD,Shagufta Shaheen, MD Experts discuss the challenges of sequencing treatments like cabozantinib and managing side effects in patients with metastatic disease.
CABINET Study and Cabozantinib for Treatment of NETS
ByNamrata (Neena) Vijayvergia, MD,Junaid Arshad, MD, MS,Aman Chauhan, MD,Andrew E. Hendifar, MD,Shagufta Shaheen, MD Dr. Chauhan discusses the groundbreaking CABINET trial, revealing its impact on treating neuroendocrine tumors and the future of oncology research.
Patient with NETS Post PRRT in Second-Line
ByNamrata (Neena) Vijayvergia, MD,Junaid Arshad, MD, MS,Aman Chauhan, MD,Andrew E. Hendifar, MD,Shagufta Shaheen, MD Experts discuss treatment options for a young patient with pancreatic neuroendocrine tumor and liver metastases, focusing on targeted therapies.
Treatment Options for High Grade (Grade 3) NETS
ByNamrata (Neena) Vijayvergia, MD,Junaid Arshad, MD, MS,Aman Chauhan, MD,Andrew E. Hendifar, MD,Shagufta Shaheen, MD Doctor Hendifer discusses the diverse therapies for neuroendocrine neoplasms, emphasizing individualized treatment based on patient needs and disease characteristics.
Sequencing of Systemic NETS Treatments
ByNamrata (Neena) Vijayvergia, MD,Junaid Arshad, MD, MS,Aman Chauhan, MD,Andrew E. Hendifar, MD,Shagufta Shaheen, MD Experts discuss advanced treatment options for neuroendocrine tumors, highlighting PRRT, mTOR inhibitors, and emerging therapies for improved patient outcomes.
Inadequate Response and Second-Line Treatment of NETS
ByNamrata (Neena) Vijayvergia, MD,Junaid Arshad, MD, MS,Aman Chauhan, MD,Andrew E. Hendifar, MD,Shagufta Shaheen, MD Oncology treatment decisions hinge on tumor biology and patient factors, emphasizing a multidisciplinary approach for optimal care.
Site of Origin and Treatment of NETS
ByNamrata (Neena) Vijayvergia, MD,Junaid Arshad, MD, MS,Aman Chauhan, MD,Andrew E. Hendifar, MD,Shagufta Shaheen, MD Experts discuss treatment strategies for neuroendocrine tumors, emphasizing personalized approaches based on tumor grade, symptoms, and patient health.
First-Line Treatment and Standard of Care for NETS
ByNamrata (Neena) Vijayvergia, MD,Junaid Arshad, MD, MS,Aman Chauhan, MD,Andrew E. Hendifar, MD,Shagufta Shaheen, MD Explore the complexities of treating neuroendocrine tumors, focusing on patient-specific strategies and the role of somatostatin analogs.
Prognostic Factors for Neuroendocrine Tumors
ByNamrata (Neena) Vijayvergia, MD,Junaid Arshad, MD, MS,Aman Chauhan, MD,Andrew E. Hendifar, MD,Shagufta Shaheen, MD Experts discuss key factors influencing disease prognosis, emphasizing differentiation, growth pace, and disease burden in treatment decisions.
Role of Biomarkers in Diagnosis and Management of NETS
ByNamrata (Neena) Vijayvergia, MD,Junaid Arshad, MD, MS,Aman Chauhan, MD,Andrew E. Hendifar, MD,Shagufta Shaheen, MD Experts discuss the evolution of neuroendocrine tumor classification, highlighting its clinical implications and the importance of standardized treatment approaches.
Early Diagnosis of Neuroendocrine Tumors
ByNamrata (Neena) Vijayvergia, MD,Junaid Arshad, MD, MS,Aman Chauhan, MD,Andrew E. Hendifar, MD,Shagufta Shaheen, MD Experts discuss the evolution of neuroendocrine tumor classification, highlighting its impact on diagnosis, treatment, and clinical implications.
Imaging Modalities for Neuroendocrine Tumors
ByNamrata (Neena) Vijayvergia, MD,Junaid Arshad, MD, MS,Aman Chauhan, MD,Andrew E. Hendifar, MD,Shagufta Shaheen, MD Imaging Modalities for Neuroendocrine Tumors
Classification of Neuroendocrine Tumors
ByNamrata (Neena) Vijayvergia, MD,Junaid Arshad, MD, MS,Aman Chauhan, MD,Andrew E. Hendifar, MD,Shagufta Shaheen, MD Classification of Neuroendocrine Tumors
Aman Chauhan, MD, discusses future directions with Lutathera in gastroenteropancreatic neuroendocrine tumors.
Aman Chauhan, MD, a medical oncologist at the University of Kentucky, discusses key recent advances in therapeutics for patients with neuroendocrine tumors, and points to the future with ongoing combination studies.
Aman Chauhan, MD, a medical oncologist at the University of Kentucky, discusses the role of Lutathera in neuroendocrine tumors.
Aman Chauhan, MD, discusses sequencing decisions when treating patients with gastroenteropancreatic neuroendocrine tumors.
Aman Chauhan, MD, discusses the role of somatostatin analogs in treating patients with gastroenteropancreatic neuroendocrine tumors.
